These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32080993)

  • 1. The Author's Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR.
    Lim J; Jeon S; Shin HY; Kim MJ; Seong YM; Lee WJ; Choe KW; Kang YM; Lee B; Park SJ
    J Korean Med Sci; 2020 Feb; 35(7):e89. PubMed ID: 32080993
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR.
    Kim JY
    J Korean Med Sci; 2020 Feb; 35(7):e88. PubMed ID: 32080992
    [No Abstract]   [Full Text] [Related]  

  • 3. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR.
    Lim J; Jeon S; Shin HY; Kim MJ; Seong YM; Lee WJ; Choe KW; Kang YM; Lee B; Park SJ
    J Korean Med Sci; 2020 Feb; 35(6):e79. PubMed ID: 32056407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darunavir does not prevent SARS-CoV-2 infection in HIV patients.
    Riva A; Conti F; Bernacchia D; Pezzati L; Sollima S; Merli S; Siano M; Lupo A; Rusconi S; Cattaneo D; Gervasoni C
    Pharmacol Res; 2020 Jul; 157():104826. PubMed ID: 32325127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir.
    Mas Serrano M; Pérez-Sánchez JR; Portela Sánchez S; De La Casa-Fages B; Mato Jimeno V; Pérez Tamayo I; Grandas F
    J Neurol Sci; 2020 Aug; 415():116944. PubMed ID: 32531579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
    Cao B; Wang Y; Wen D; Liu W; Wang J; Fan G; Ruan L; Song B; Cai Y; Wei M; Li X; Xia J; Chen N; Xiang J; Yu T; Bai T; Xie X; Zhang L; Li C; Yuan Y; Chen H; Li H; Huang H; Tu S; Gong F; Liu Y; Wei Y; Dong C; Zhou F; Gu X; Xu J; Liu Z; Zhang Y; Li H; Shang L; Wang K; Li K; Zhou X; Dong X; Qu Z; Lu S; Hu X; Ruan S; Luo S; Wu J; Peng L; Cheng F; Pan L; Zou J; Jia C; Wang J; Liu X; Wang S; Wu X; Ge Q; He J; Zhan H; Qiu F; Guo L; Huang C; Jaki T; Hayden FG; Horby PW; Zhang D; Wang C
    N Engl J Med; 2020 May; 382(19):1787-1799. PubMed ID: 32187464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lopinavir-ritonavir in severe COVID-19.
    Stower H
    Nat Med; 2020 Apr; 26(4):465. PubMed ID: 32273604
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Trial of Lopinavir-Ritonavir in Covid-19. Reply.
    Cao B; Zhang D; Wang C
    N Engl J Med; 2020 May; 382(21):e68. PubMed ID: 32369286
    [No Abstract]   [Full Text] [Related]  

  • 11. A Trial of Lopinavir-Ritonavir in Covid-19.
    Carmona-Bayonas A; Jimenez-Fonseca P; Castañón E
    N Engl J Med; 2020 May; 382(21):e68. PubMed ID: 32369285
    [No Abstract]   [Full Text] [Related]  

  • 12. A Trial of Lopinavir-Ritonavir in Covid-19.
    Corrao S; Natoli G; Cacopardo B
    N Engl J Med; 2020 May; 382(21):e68. PubMed ID: 32369284
    [No Abstract]   [Full Text] [Related]  

  • 13. A Trial of Lopinavir-Ritonavir in Covid-19.
    Havlichek D
    N Engl J Med; 2020 May; 382(21):e68. PubMed ID: 32369283
    [No Abstract]   [Full Text] [Related]  

  • 14. A Trial of Lopinavir-Ritonavir in Covid-19.
    Kunz KM
    N Engl J Med; 2020 May; 382(21):e68. PubMed ID: 32369282
    [No Abstract]   [Full Text] [Related]  

  • 15. A Trial of Lopinavir-Ritonavir in Covid-19.
    Dalerba P; Levin B; Thompson JL
    N Engl J Med; 2020 May; 382(21):e68. PubMed ID: 32369281
    [No Abstract]   [Full Text] [Related]  

  • 16. In COVID-19, adding lopinavir-ritonavir to usual care did not shorten time to clinical improvement.
    Yang P; Tekwani S; Martin GS
    Ann Intern Med; 2020 Jun; 172(12):JC63. PubMed ID: 32539520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?
    Baldelli S; Corbellino M; Clementi E; Cattaneo D; Gervasoni C
    J Antimicrob Chemother; 2020 Sep; 75(9):2704-2706. PubMed ID: 32407513
    [No Abstract]   [Full Text] [Related]  

  • 18. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.
    Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T
    Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
    Cheng CY; Lee YL; Chen CP; Lin YC; Liu CE; Liao CH; Cheng SH
    J Microbiol Immunol Infect; 2020 Jun; 53(3):488-492. PubMed ID: 32331982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.